Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Leiomyosarcoma: early-phase trial registry
9 of 17 indexed Leiomyosarcoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,004 of 28,707 conditions by registered trial count.
17 US clinical trials · 9 currently recruiting · #1,004 of 28,707 conditions by registered trial count
Leiomyosarcoma: 17 US clinical trials tracked, 9 recruiting.
Leiomyosarcoma is the subject of 17 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 11 in Phase 1-2 (earlier-stage). The most active sponsor is University of Michigan Rogel Cancer Center, running 2 of these trials.
Enrollment posture brief
Registry condition leiomyosarcoma
OPEN 9 | RECR 53% | LATE 3 | EARLY 11 | RANK #1004 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adenoid Cystic Carcinoma (53% recruiting · 17 trials)
Leiomyosarcoma lists 9 open slots (53% of 17 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Leiomyosarcoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Leiomyosarcoma is recruiting above its size-band peers.
9 of 17 indexed trials (52.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Leiomyosarcoma trials is spread across many organizations.
University of Michigan Rogel Cancer Center accounts for 2 of 17 trials (11.8%). 15 distinct sponsors appear on at least one study for this condition label.
-
Most Leiomyosarcoma trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 17 trials that report a genuine target (sentinel values excluded). 12 of those (70.6%) plan for fewer than 100 participants.
-
Leiomyosarcoma research is mostly interventional.
14 interventional and 3 observational studies make up this index (82.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
17 total, page 1 of 1
Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo)
PharmaMar
NCT06088290
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
Advenchen Laboratories
NCT03016819
Beliefs, Attitudes, and Response to Genetic Testing in SarcomaPatients
University of Utah
NCT06875700
Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma
European Organisation for Research and Treatment of Cancer - EORTC
NCT04031677
Metastatic Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
NCT05653388
Metronomic Trabectedin, Gemcitabine, and Dacarbazine for Soft Tissue Sarcoma
Sarcoma Oncology Research Center
NCT04535271
Localized Leiomyosarcoma Biomarker Protocol
University of Michigan Rogel Cancer Center
NCT04925089
A Phase I Trial of Combination Gemcitabine and Nab-Sirolimus in Advanced Leiomyosarcomas or Advanced Soft-Tissue Sarcomas With TSC2 or TSC1 Loss-of-function Mutations or Deletions
M.D. Anderson Cancer Center
NCT06308419
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Gabriel Tino
NCT06528769
Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery
National Cancer Institute (NCI)
NCT02923778
A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma
Memorial Sloan Kettering Cancer Center
NCT04624178
Nivolumab and BO-112 Before Surgery for the Treatment of Resectable Soft Tissue Sarcoma
Jonsson Comprehensive Cancer Center
NCT04420975
LMP-specific T-cells for Patients With Relapsed EBV-positive Lymphoma
Baylor College of Medicine
NCT00062868
A Study of Unesbulin (PTC596) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)
PTC Therapeutics
NCT03761095
A Study of Nivolumab in Selected Uterine Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT03241745
Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma
Dana-Farber Cancer Institute
NCT00856050
Bevacizumab and Radiation Therapy for Sarcomas
Massachusetts General Hospital
NCT00356031
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 4 |
| Phase 2 | 7 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Leiomyosarcoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Leiomyosarcoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Leiomyosarcoma page
17 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Leiomyosarcoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Michigan Rogel Cancer Center sponsors the most Leiomyosarcoma trials on record, review their full trial history before evaluating a specific study. See University of Michigan Rogel Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Leiomyosarcoma condition card totals 17 registered trials; most-linked intervention Radiation Therapy; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.